StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)

Close on Nov 17, 2026Market cap $2.39MP/E –Yield –

20/20 Biolabs revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $2.05M, up 16.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.05M+16.7%
FY2024Dec 31, 2024$1.75M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$730.57K–
Q1 FY2026Mar 31, 2026$353.38K–
Q2 FY2025Jun 30, 2025$535.06K–
Q1 FY2025Mar 31, 2025$553.82K–

More 20/20 Biolabs figures

See a number that looks wrong?